Christopher L. Carpenter

Oncology

25 Church St
Wilkes Barre, PA 18702

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6 publications

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.

Journal: Cancer immunology, immunotherapy : CII

Published: February 26, 2021

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Journal: Nature communications

Published: February 23, 2021

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

Journal: JNCI cancer spectrum

Published: May 02, 2019

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.

Journal: Haematologica

Published: June 04, 2018

Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.

Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.

Journal: Structure (London, England : 1993)

Published: August 23, 2015

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Journal: Cancer cell

Published: February 04, 2015

Showing 1-6 of 6

Last Updated: 09/26/2026